Precision Medicine Podcast · Trapelo

Dr. William Oh on How Precision Medicine and Early Detection Transform Outcomes in Prostate Cancer Care (Part 1)

·42 min·2 clips
Black men should begin PSA conversations in their early 40s, between 40 and 45.
1. Precision Medicine Podcast Season 6 centers on prostate cancer, a disease Karen Cushman says is the most common cancer in U.S. men after skin cancer and the second cause of cancer mortality. 2. Karen Cushman hosts and produces the show, and Dr. William Oh joins as a genitourinary oncologist, Yale precision-medicine director, and chair of the American Cancer Society National Prostate Cancer Roundtable. 3. The episode asks how screening, access, and precision medicine can improve outcomes in prostate cancer while a 3% yearly increase in cases and a 5% yearly increase in advanced stages continue. 4. Oh traces his career from being born in Korea, moving to Long Island as an infant, and coming to Yale as an undergraduate at 18 because he wanted to use medicine and science to improve the world. 5. He describes the prostate as a small walnut-sized organ in front of the rectum whose role is not fully clear but may be important for fertility and sperm processing. 6. Oh says benign prostatic hypertrophy is common with age, causes more frequent urination, and is not linked to cancer. 7. He says prostate cancer is a disease of aging and that the true cause of the disease remains unclear. 8. On the American Cancer Society roundtable, Oh says the group was created because prostate-cancer incidence and mortality trends are worsening in the United States and worldwide. 9. He says the roundtable is an organization of organizations that brings together advocacy groups, scientific groups, academic centers, and navigation groups. 10. Oh says one priority is improving access to treatments, noting that more than a dozen survival-improving drugs now exist after a period when none did. 11. He says a standard hormone-blocking drug can improve survival in metastatic prostate cancer by 20% to 40%, yet only about half of U.S. men with advanced disease receive it at diagnosis. 12. Oh says another priority is building databases to understand why men do not receive the right drugs and where the barriers sit. 13. He identifies screening as the other major priority and says prostate-cancer screening remains controversial because the disease has a long natural history. 14. Oh says the mortality trend had improved after PSA screening was first recommended, but now appears to be plateauing and may start rising again. 15. He cites a Lancet Commission estimate that global prostate-cancer deaths could increase by 85% over the next 10 to 15 years. 16. Oh argues that backlash against screening and concern about over-detection may have contributed to more men presenting with advanced disease. 17. On Black men, Oh says the disparity is longstanding, with higher incidence and death rates than White men and earlier ages at diagnosis. 18. He says the PCF guideline panel used randomized trial data, modeling data, and observational data because Black men are underrepresented in the trials that usually guide screening policy. 19. Oh explains that the panel recommended Black men begin PSA conversations between ages 40 and 45, get a baseline PSA, consider annual screening, and discuss stopping around age 70. 20. The conversation is interview-style and policy-heavy, with long answers from Oh and follow-up questions from Karen Cushman on biology, equity, biomarkers, and implementation.

As heard by us

A careful prostate-cancer conversation about risk, screening, and who is too often missed.

Prostate cancer sits at the center of a discussion about screening, risk, and patient-centered care. Dr. William Oh and Karen Cushman keep the focus on the uneven ground under screening guidance, especially the higher burden borne by Black men and the limits of evidence when the…

Read the full review in PlayNext →
Listen to the show on